Dr. Calais is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Medical Plaza Suite B114
Los Angeles, CA 90095Phone+1 310-794-1005Fax+1 310-206-7760
Summary
- Assistant Professor at the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology. Dr. Calais received his MD degree from the University of Paris-Diderot in 2010. He subsequently trained in nuclear medicine and cancer imaging at the Henri Becquerel Cancer Center of the University of Rouen and was board certified by the French Society of Nuclear Medicine in 2014. His work focuses on improving the outcomes of cancer patients by translating and applying novel diagnostic and therapeutic approaches. He uses PET/CT imaging for cancer phenotyping, radiation therapy planning and therapy response assessment. He leads the clinical research program of Nuclear Medicine and Theranostics at UCLA that combines radionuclide therapy and imaging.
Education & Training
- University of Paris VII Faculty of MedicineClass of 2010
Certifications & Licensure
- CA State Medical License 2020 - 2024
Clinical Trials
- Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer Start of enrollment: 2020 Aug 14
- Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy Start of enrollment: 2022 Jan 13
Roles: Contact, Principal Investigator
- Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) Start of enrollment: 2024 Jul 01
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Corrigendum to "Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Resul...Wesley R Armstrong, Amar U Kishan, Kiara M Booker, Tristan R Grogan, David Elashoff
European Urology. 2025-01-01 - Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Confere...Alan H Bryce, Neeraj Agarwal, Himisha Beltran, Maha H Hussain, Oliver Sartor
Cancer. 2025-01-01 - FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.Rong Rong Huang, Chunlai Zuo, Christine E Mona, Adrien Holzgreve, Colm Morrissey
Journal of Nuclear Medicine. 2024-12-03
Press Mentions
- Breakthrough Imaging Techniques Reveal Concealed Metastases in High-Risk Prostate Cancer PatientsJanuary 3rd, 2025
- Advanced Imaging Uncovers Hidden Metastases in High-Risk Prostate Cancer CasesJanuary 3rd, 2025
- HMN 2025: Advanced Imaging Reveals Hidden Metastases in High-Risk Prostate Cancer CasesJanuary 3rd, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: